Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

William (Bill) Hyun - aVenture Research

William (Bill) Hyun

AddedMar 31, 2024

UpdatedOct 15, 2026

William (Bill) Hyun

William (Bill) Hyun

Founder, BioInfleXion Point Partners

William (Bill) Hyun's Career

BioInfleXion Point Partners

Belmont, CA, US

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

William (Bill) Hyun's Investments

1 investments since 2017

1 operating

Investments view

Group by

2017

1

Akadeum Life Sciences
Series Unknown · September 2017$1.5M
Series Unknown · September 2017

Founder

Scribe Biosciences

Seed$3.1MSan Francisco, CA, US

Board Member· Board

Vitra Bioscience

Series A$5.5MMountain, WI, US

Founder

Fluent BioSciences

Series A$22.9MWatertown, MA, US

Board Member· Board

Co-Founder

Slingshot Biosciences

Series A$34MEmeryville, CA, US

Board Member· Board

Akadeum Life Sciences

Series B$21.5MAnn Arbor, MI, US

Board Member· Board

Mission Bio

Series C$150.9MSouth San Francisco, CA, US

Board Member· Board

People Similar to William (Bill) Hyun

Jack BallBoard Member · Cytek Biosciences

Joe McMahonCEO · Bioventure Partners

Similar to BioInfleXion Point Partners

OnPoint AdvisorsDallas, TX, USFinancial Servicesest. 2018OnPoint AdvisorsDallas, TX, US · est. 2018

Dallas-based OnPoint facilitates capital formation and private investment in diverse industries.

Similar to Vitra Bioscience

CelldomDurham, NC, USSingle-Cell Analysisest. 2016CelldomDurham, NC, US · est. 2016

Celldom advances research and drug development with high-throughput, next-gen single-cell analysis technology.

Cytek BiosciencesFremont, CA, USScientific Instrumentsest. 2014Cytek BiosciencesFremont, CA, US · est. 2014

Biotech firm specializing in the production of scientific instruments.

Public · $144.3M583

Cytomics AnalyticalWest Lafayette, IN, USCell Analysis, Softwareest. 2002Cytomics AnalyticalWest Lafayette, IN, US · est. 2002

Indiana-based Cytomics Analytical offers advanced, high-speed cell analysis solutions and tools.

Partillion BioscienceLos Angeles, CA, USLife Scienceest. 2020Partillion BioscienceLos Angeles, CA, US · est. 2020

Partillion Bioscience: A life science company innovating single-cell analysis for probing biological functions.

Leadership at Scribe Biosciences

Russell ColeCo-Founder

Maithreyan SrinivasanCo-Founder

Similar to Scribe Biosciences

ImmunaiNew York City, NY, USBiomarkers, Biotechest. 2018ImmunaiNew York City, NY, US · est. 2018

Immunai, a biotech firm, uses single-cell genomics and ML for high-resolution immune profiling and biomarker discovery.

Series B · $295M167

Scribe TherapeuticsAlameda, CA, USCrispr Therapeuticsest. 2017Scribe TherapeuticsAlameda, CA, US · est. 2017

Scribe: A biotech firm innovating CRISPR-based solutions to rectify genetic disorders.

Series B · $120M121

BioSkryb GenomicsDurham, NC, USGenomic Toolsest. 2018BioSkryb GenomicsDurham, NC, US · est. 2018

BioSkryb Genomics: Transforming single cell discovery with advanced genomic tools for disease management.

Series A · $31.5M83

ImmunoMindBerkeley, CA, USDrug Discovery, T-Cell Therapyest. 2020ImmunoMindBerkeley, CA, US · est. 2020

Single-cell tech & AI platform for T-cell therapy drug discovery & development.

Pre-Seed · $755k14

Leadership at Fluent BioSciences

Mike DybbsBoard Member

Wouter MeulemanBoard Member

Tim HarknessBoard Member

Gary ZweigerCo-Founder

Sepehr KianiCo-Founder

Adam AbateBoard Member

Similar to Fluent BioSciences

Parse BiosciencesSeattle, WA, USData Analysis, Sequencingest. 2018Parse BiosciencesSeattle, WA, US · est. 2018

Seattle-based Parse Biosciences offers scalable single-cell sequencing platforms to accelerate scientific research.

Series C · $100M119

Leadership at Slingshot Biosciences

Corey RitterBoard Member

Jeff KimFounder

Adam WieschhausBoard Member

Similar to Slingshot Biosciences

SynlifeCambridge, MA, USMedical Researchest. 2017SynlifeCambridge, MA, US · est. 2017

Synlife: Innovating therapeutic and diagnostic solutions through engineered synthetic cells for medical research.

Think BioscienceBoulder, CO, USMedicinesest. 2019Think BioscienceBoulder, CO, US · est. 2019

Think Bioscience innovates synthetic biology, designing superior medicines using living systems.

Seed · $17.3M26

CellanomePalo Alto, CA, USSynthetic Biologyest. 2020CellanomePalo Alto, CA, US · est. 2020

Cellanome, a synthetic biology firm, leverages a multi-omics platform for innovative molecular solutions.

Series A · $63.7M33

SpheringenicsAtlanta, GA, USCell Therapiesest. 2007SpheringenicsAtlanta, GA, US · est. 2007

SpherIngenics: Leading biotech firm specializing in innovative cell-based medicinal therapies.

Leadership at Akadeum Life Sciences

Brandon McNaughtonFounder & CEO

Dan KidleBoard Member

Similar to Akadeum Life Sciences

LevitasBioMenlo Park, CA, USBiotech, Cell Separationest. 2017LevitasBioMenlo Park, CA, US · est. 2017

LeviCell: A pioneering platform offering fast, reliable, and gentle label-free cell separation.

Series C · $61M58

CytoMagSunnyvale, CA, USCell Analysisest. 2012CytoMagSunnyvale, CA, US · est. 2012

CytoMag provides rapid cell isolation and analysis through microfluidic systems.

CytoRecoveryBlacksburg, VA, USCell Sorting, Microfluidicsest. 2017CytoRecoveryBlacksburg, VA, US · est. 2017

CytoRecovery: Pioneering microfluidic technology for efficient recovery and analysis of biological cells.

IkotechNew Albany, IN, USCell Sortingest. 2005IkotechNew Albany, IN, US · est. 2005

IKOTECH LLC: Pioneering high-speed magnetic cell sorting systems for advanced medical treatments.

Seed · $275k14

Leadership at Mission Bio

Brian KimBoard Member

Adam AbateCo-Founder

Charlie SilverCo-Founder

Allison BallmerBoard Member

Dennis EastburnCo-Founder

Adam SciambiCo-Founder

Similar to Mission Bio

MiodxSan Jose, CA, USCancer Biomarkersest. 2014MiodxSan Jose, CA, US · est. 2014

MIODx® develops cancer biomarkers using its ClonoMap platform to enhance medical outcomes through T cell profiling.

Enumera MolecularAnn Arbor, MI, USLife Science Toolsest. 2022

Enumera MolecularAnn Arbor, MI, US · est. 2022

Enumera Molecular: Innovating low-cost, rapid clinical testing with scalable life science tools.

Series A · $12.5M23

RealSeq BiosciencesSanta Cruz, CA, USLibrary Construction, RNA Sequencingest. 2019RealSeq BiosciencesSanta Cruz, CA, US · est. 2019

RealSeq Biosciences specializes in bias-free small RNA NGS library construction, targeted NGS tools, and cf-RNA analysis.

FlexomicsBoston, MA, USScreening Platformest. 2019FlexomicsBoston, MA, US · est. 2019

Flexomics: A high-throughput screening platform bridging genomic and functional analysis.

NantOmicsCulver City, CA, USMolecular Testingest. 2013

NantOmicsCulver City, CA, US · est. 2013

NantOmics: A leading biotech firm in Culver City, CA, pioneering personalized cancer treatment options.

Series A · $250.8M32

Mitra BiotechWoburn, MA, USCancer Treatmentest. 2010Mitra BiotechWoburn, MA, US · est. 2010

Mitra Biotech: Pioneering personalized cancer treatments through innovative biotechnology since 2010.

Series C · $43.8M61

YourBio HealthCambridge, MA, USMedical Devicesest. 2008YourBio HealthCambridge, MA, US · est. 2008

YourBio Health develops innovative products to simplify diagnostic medicine, enhancing blood sampling and testing.

Series C · $98.2M33